LKF Laboratorium fuer Klinische Forschung
LKF Laboratorium fuer Klinische Forschung is recorded as a service provider in 27 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 27 trials · Latest update first
A phase 2, multicentre, open-label, single arm study to evaluate the effectiveness and safety of rezafungin (as acetate) in the treatment of chronic pulmonary aspergillosis (CPA) in patients with limited treatment options
Sponsor Mundipharma Research Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 2b, Multicenter, Double-Blind, Randomized, Placebo-controlled Trial Evaluating Efficacy and Safety of Subcutaneous Doses of Navepegritide Administered Once Weekly for 52 Weeks in Adolescents (12-<18 Years of Age) with Achondroplasia
Sponsor Ascendis Pharma Growth Disorders A/S
- Start (EU)
- Latest update
- Estimated end
- Not reported
A randomised, double-blind, double-dummy, multicentre, phase III, non inferiority trial of an oral mesalazine formulation in patients with active mild to moderate ulcerative colitis for the induction of remission.
Sponsor Faes Farma S.A.
- Start (EU)
- Latest update
- Estimated end
AttaCH: A Phase 2, Multicenter, Long-Term, Open Label Extension Trial Evaluating Safety, Tolerability, and Efficacy of Subcutaneous Doses of TransCon CNP Administered Once Weekly in Children and Adolescents with Achondroplasia
Sponsor Ascendis Pharma Growth Disorders A/S
- Start (EU)
- Latest update
- Estimated end
A Single Group Treatment, Phase 2 study to investigate Pharmacokinetics, Safety and Tolerability of Cefepime-Enmetazobactam administered by intra-venous infusion over 2 hours in Male or Female Participants from birth to less than 18 years of age hospitalized with complicated urinary tract infections (cUTI) including Acute Pyelonephritis (AP).
Sponsor Orchid Pharma Europe GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Multicenter, Open-Label, Dose-Finding Clinical Trial to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of RVU120 in Combination with Venetoclax in Participants with Acute Myeloid Leukemia Who Failed Prior Therapy with Venetoclax and a Hypomethylating Agent (RIVER-81)
Sponsor Ryvu Therapeutics S.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
(19429) A phase 1/2 open-label safety and dose-finding study of BAY 2599023 (DTX201), an adeno-associated virus (AAV) hu37-mediated gene transfer of B-domain deleted human factor VIII, in adults with severe hemophilia A
Sponsor Bayer AG
- Start (EU)
- Latest update
- Estimated end
A Phase 3, randomized, parallel-group, double-blind, multicenter study investigating the safety and efficacy of NT 201 compared with placebo in adult participants with moderate to severe platysma prominence in Europe
Sponsor Merz Aesthetics GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 2, Open-Label, 156-week Trial to Investigate the Efficacy, Safety and Tolerability of Once Weekly Navepegritide and Lonapegsomatropin in Children with Achondroplasia
Sponsor Ascendis Pharma Growth Disorders A/S
- Start (EU)
- Latest update
- Estimated end
(21824) A phase 3, single group treatment, open-label study to evaluate the safety of BAY 94-9027 infusions for prophylaxis and treatment of bleeding in previously treated children aged 7 to <12 years with severe hemophilia A
Sponsor Bayer Consumer Care AG
- Start (EU)
- Latest update
- Estimated end
A Multicenter, Open-Label Clinical Trial of RVU120 in Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia with or without NPM1 Mutation (RIVER-52)
Sponsor Ryvu Therapeutics S.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 2, Multicenter, Double-Blind, Randomized, Placebo-controlled Trial, evaluating Safety, Tolerability, and Efficacy of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in Infants (0 to <2 years of age) with Achondroplasia followed by an Open Label Extension (OLE) period.
Sponsor Ascendis Pharma Growth Disorders A/S
- Start (EU)
- Latest update
- Estimated end
A multicentre, prospective, open-label, uncontrolled Phase 3 study to assess the efficacy, safety and pharmacokinetics of Atenativ in patients with congenital antithrombin deficiency undergoing surgery or delivery
Sponsor Octapharma AG
- Start (EU)
- Latest update
- Estimated end
International Phase III, Multi-center, Randomized, Double-blind, Placebo and Active-controlled and Parallel group Clinical Trial to Evaluate the Efficacy and Safety of Oral Minoxidil 1 mg in Female patients with Androgenetic Alopecia.
Sponsor Industrial Farmaceutica Cantabria S.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A double-blind, randomized, placebo-controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms caused by adjuvant endocrine therapy, over 52 weeks and optionally for additional up to 3.5 years in women with, or at high risk for developing hormone-receptor positive breast cancer
Sponsor Bayer Consumer Care AG
- Start (EU)
- Latest update
- Estimated end
Investigation of 3 different doses of a newly developed vaginal ring releasing estriol for the treatment of vaginal atrophy - a placebo-controlled, double-blind, combined dose-finding and proof-of-concept trial with parallel-group design in postmenopausal women
Sponsor SocraTec R&D Concepts in Drug Research and Development GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
MOdern Treatment of Inhibitor-PositiVe PATiEnts with Haemophilia A – An International Low-Interventional Pragmatic Investigator Initiated Trial
Sponsor HZRM Haemophilie-Zentrum Rhein Main GmbH
- Start (EU)
- Latest update
- Estimated end
An open label study followed by a randomised, double-blind, placebo-controlled, parallel group and an extension study to investigate the safety and efficacy of GB1211 (a galectin-3 inhibitor) in combination with atezolizumab in patients with Non-Small Cell Lung Cancer (NSCLC).
Sponsor Galecto Biotech AB
- Start (EU)
- Latest update
- Estimated end
- Not reported
Multicenter, Phase Ib/IIa Study on the Safety and Efficacy of Autologous Peptide-coupled Red Blood Cells in Patients with Relapsing Remitting Multiple Sclerosis
Sponsor Cellerys AG
- Start (EU)
- Latest update
- Estimated end
Prospective, open-label, single-arm, multicentre Phase 3 study to evaluate the pharmacokinetics, efficacy, tolerability, and safety of subcutaneous human immunoglobulin (Newnorm) in patients with primary immunodeficiency diseases
Sponsor Octapharma Pharmazeutika Produktionsgesellschaft mbH
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for LKF Laboratorium fuer Klinische Forschung?
The 2026-10-09 snapshot links LKF Laboratorium fuer Klinische Forschung to 27 distinct CTIS trials. Recorded services include Laboratory services, hs-Troponin I, Study supplies / Anxillary supplies procurement and distribution, Biological Specimens, among 7 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for LKF Laboratorium fuer Klinische Forschung?
The most frequently recorded therapeutic areas are Genetic and Congenital Disorders, Musculoskeletal, Infectious Disease, Blood Disorders. Recorded phases include Phase 2, Phase 3, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to LKF Laboratorium fuer Klinische Forschung conducted?
The linked trials record locations in 22 countries, including Spain, Germany, France, Italy, Poland. These are trial locations, not confirmed office locations or countries where LKF Laboratorium fuer Klinische Forschung delivered services.
What can this page tell me about LKF Laboratorium fuer Klinische Forschung's trial experience?
Browse 27 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under LKF Laboratorium fuer Klinische Forschung. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- LKF Laboratorium fuer Klinische Forschung GmbH